EBS News and Press, Emergent Biosolutions Inc. From 02/21/19

GAITHERSBURG, Md., Feb. 21, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) reported financial results for the quarter and year ended December 31, 2018. FINANCIAL HIGHLIGHTS 2018 FINANCIAL PERFORMANCE (I) Quarter Ended December 31, 2018 (Unaudited) Revenu...

Insys Therapeutics ( INSY ) has had an agonizing past two years due to the combination of financial and legal troubles. Federal investigations into the company and former executives have hurt sales, which in turn, has decimated the share price. However, the sales of its flagship commercial p...

GAITHERSBURG, Md., Feb. 12, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced the appointment of Seamus Mulligan to the company’s Board of Directors effective March 19, 2019. Mr. Mulligan was a co-founder and principal investor of Adapt Pharma Ltd. and se...

GAITHERSBURG, Md., Feb. 07, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, February 21, 2019 at 5:00 pm (Eastern Time) to discuss the financial results for the fourth quarter and full year 2018, recent business developments, financia...

GAITHERSBURG, Md., Jan. 24, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced the appointment of Robert G. Kramer, Sr. to the company’s Board of Directors. Mr. Kramer currently serves as Emergent’s president and COO. Effective April 1, 2019, Mr. Kr...

INSYS Therapeutics ( INSY +5.1% ) is up on below-average volume in apparent reaction to a statement from FDA Commissioner Scott Gottlieb, M.D. supporting over-the-counter access for opioid overdose med naloxone, currently prescription-only. More news on: Insys Therapeutics, Inc., Emerg...

The following slide deck was published by Emergent BioSolutions Inc. in conjunction with this Read more ...

Emergent BioSolutions (NYSE: EBS ) announces preliminary FY 2018 results and 2019 outlook. More news on: Emergent BioSolutions Inc., Healthcare stocks news, Read more ...

Full year 2018 preliminary performance in line with recently revised guidance Full year 2019 forecast reflects continued growth of organic business and anticipated positive impact of recent acquisitions GAITHERSBURG, Md., Jan. 07, 2019 (GLOBE NEWSWIRE) --   Emergent BioSolutions...

GAITHERSBURG, Md., Jan. 04, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that its CEO Daniel J. Abdun-Nabi will be retiring and that its board of directors has unanimously appointed Robert G. Kramer, Sr., the company’s current president and COO, to ...